AVM
BLPH

Arch Venture Management’s Bellerophon Therapeutics, Inc. BLPH Stock Holding History

Arch Venture Management’s Portfolio BLPH Stock Details BLPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-64,377
Closed -$631K – 5
2019
Q1 		$631K Hold
64,377
– – 0.61% 5
2018
Q4 		$774K Buy
+64,377
New +$935K 0.77% 5

Other funds holding BLPH

NMVA
New Mountain Vantage Advisers New York $4.33B AUM 35.3% 1-Year Est. Return
PCM
Puissance Capital Management New York $17.3M AUM 149.36% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Arch Venture Management's BLPH Position: Q2 2019 in Review

Arch Venture Management sold out of Bellerophon Therapeutics, Inc. (BLPH) in Q2 2019, closing a stake of 64,377 shares — an estimated $631K sold.

Arch Venture Management first reported a position in BLPH in Q4 2018 and held it in 2 quarters. The position peaked at $774K in Q4 2018. 26 funds tracked by Wall St. Rank hold BLPH as of Q2 2019.

  • Arch Venture Management reported no remaining Bellerophon Therapeutics, Inc. position as of Q2 2019 after selling out during the quarter.
  • Arch Venture Management sold 64,377 Bellerophon Therapeutics, Inc. shares in Q2 2019, an estimated $631K.
  • Arch Venture Management first reported a position in Bellerophon Therapeutics, Inc. in Q4 2018 and held it in 2 quarters.
  • Arch Venture Management's Bellerophon Therapeutics, Inc. position peaked at $774K in Q4 2018.
  • 26 funds tracked by Wall St. Rank held Bellerophon Therapeutics, Inc. as of Q2 2019.

Based on Arch Venture Management's 13F filing for Q2 2019, filed 9 Aug 2019.